drugset / Trial / NCT01333878
Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage
Phase 2/3
Completed
12 enrolled
Orrin T Troum, M.D. and Medical Associates
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
The hypothesis of this study is that subcutaneous Abatacept is effective in reducing synovial inflammation, osteitis, and erosions in Rheumatoid Arthritis as assessed by low field extremity MRI and X-ray.
Timeline
- Start
- 2011-03
- Primary completion
- 2013-11
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abatacept | Other / unclassified | 125 mg | Subcutaneous |